BR0014378A - Derivados de ácido indolil-3-glioxìlico tendo propriedades terapeuticamente valiosas - Google Patents

Derivados de ácido indolil-3-glioxìlico tendo propriedades terapeuticamente valiosas

Info

Publication number
BR0014378A
BR0014378A BR0014378-2A BR0014378A BR0014378A BR 0014378 A BR0014378 A BR 0014378A BR 0014378 A BR0014378 A BR 0014378A BR 0014378 A BR0014378 A BR 0014378A
Authority
BR
Brazil
Prior art keywords
indolyl
acid derivatives
therapeutically valuable
valuable properties
glyoxylic acid
Prior art date
Application number
BR0014378-2A
Other languages
English (en)
Inventor
Bernd Nickel
Thomas Klenner
Gerald Bacher
Thomas Beckers
Peter Emig
Juergen Engel
Erik Bruyneel
Guenter Kamp
Kirsten Peters
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946301A external-priority patent/DE19946301A1/de
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Publication of BR0014378A publication Critical patent/BR0014378A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE áCIDO INDOLIL-3-GLIOXìLICO TENDO PROPRIEDADES TERAPEUTICAMENTE VALIOSAS". A invenção refere-se ao uso de indol-3-glioxilamidas N-substituídas [sic] da fórmula geral 1 para o tratamento de tumor, em particular no caso de resistência farmacêutica e metástase de carcinoma e como inibidores de angiogênese, com efeitos colaterais acentuadamente menor, em particular neurotoxicidade acentuadamente menor e produtos farmacêuticos compreendendo as mesmas.
BR0014378-2A 1999-09-28 2000-09-26 Derivados de ácido indolil-3-glioxìlico tendo propriedades terapeuticamente valiosas BR0014378A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19946301A DE19946301A1 (de) 1998-04-02 1999-09-28 Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
PCT/EP2000/009390 WO2001022954A2 (de) 1999-09-28 2000-09-26 Indolyl-3-glyoxylsäurederivate als antitumormittel

Publications (1)

Publication Number Publication Date
BR0014378A true BR0014378A (pt) 2003-07-29

Family

ID=7923485

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014378-2A BR0014378A (pt) 1999-09-28 2000-09-26 Derivados de ácido indolil-3-glioxìlico tendo propriedades terapeuticamente valiosas

Country Status (32)

Country Link
EP (1) EP1218006B1 (pt)
JP (1) JP2003510274A (pt)
KR (1) KR100759242B1 (pt)
CN (1) CN1301712C (pt)
AR (1) AR025885A1 (pt)
AT (1) ATE459356T1 (pt)
AU (1) AU783436B2 (pt)
BG (1) BG106639A (pt)
BR (1) BR0014378A (pt)
CA (1) CA2386069C (pt)
CZ (1) CZ303246B6 (pt)
DE (1) DE50015879D1 (pt)
DZ (1) DZ3196A1 (pt)
EE (1) EE200200169A (pt)
ES (1) ES2342042T3 (pt)
GE (1) GEP20043250B (pt)
HK (1) HK1048941B (pt)
HR (1) HRP20020369A2 (pt)
HU (1) HUP0202788A3 (pt)
IL (2) IL148670A0 (pt)
IS (1) IS6319A (pt)
MX (1) MXPA02002824A (pt)
NO (1) NO322614B1 (pt)
NZ (1) NZ517988A (pt)
PL (1) PL199576B1 (pt)
RS (1) RS51302B (pt)
RU (1) RU2282444C2 (pt)
SK (1) SK287533B6 (pt)
TW (1) TWI269654B (pt)
UA (1) UA75872C2 (pt)
WO (1) WO2001022954A2 (pt)
ZA (1) ZA200202556B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
EP1484329A1 (de) * 2003-06-06 2004-12-08 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
EP1595878A1 (de) * 2004-05-15 2005-11-16 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
CN1816543B (zh) * 2003-06-05 2011-01-19 赞塔里斯有限公司 具有细胞凋亡诱导效应的吲哚衍生物
US20050124623A1 (en) 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
DK2447252T3 (da) * 2004-05-23 2020-03-16 Hmi Medical Innovations Llc Theramuteinmodulatorer
US20060110462A1 (en) * 2004-11-08 2006-05-25 Pavlos Papadopoulos Nanoparticulate compositions of tubulin inhibitor compounds
US20060100432A1 (en) 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
EP1848430B1 (en) 2004-12-31 2017-08-02 Dr. Reddy's Laboratories Ltd. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
EP2091532A1 (en) * 2006-11-28 2009-08-26 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
WO2013024358A2 (en) 2011-08-18 2013-02-21 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
WO2013046045A1 (en) 2011-09-27 2013-04-04 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN109111501B (zh) * 2017-06-23 2022-04-22 首都医科大学 脂肪氨基酸修饰的吲哚乙醇衍生物, 其合成，活性和应用
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
JP3163631B2 (ja) * 1992-10-20 2001-05-08 東レ株式会社 好酸球浸潤抑制剤
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
WO1998045431A1 (fr) 1997-04-08 1998-10-15 Banyu Pharmaceutical Co., Ltd. Gene associe a la metastase cancereuse
TR200002447T2 (tr) * 1998-02-25 2000-11-21 Genetics Institute, Inc. Fosfolinaz enzimlerinin inhibitörleri
JP2004500308A (ja) * 1998-03-12 2004-01-08 ノボ　ノルディスク　アクティーゼルスカブ プロテインチロシンホスアターゼのモジュレーター
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
IL138847A0 (en) * 1998-04-28 2001-10-31 Dresden Arzneimittel New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same
JP2000239252A (ja) * 1999-02-16 2000-09-05 Mitsubishi Chemicals Corp インドール誘導体
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof

Also Published As

Publication number Publication date
NO20021367D0 (no) 2002-03-19
CZ20021005A3 (cs) 2004-01-14
KR20030019295A (ko) 2003-03-06
YU22702A (sh) 2004-12-31
ATE459356T1 (de) 2010-03-15
IL148670A (en) 2009-09-01
SK4072002A3 (en) 2003-11-04
KR100759242B1 (ko) 2007-09-18
DZ3196A1 (fr) 2001-04-05
MXPA02002824A (es) 2003-07-21
PL364811A1 (en) 2004-12-13
CA2386069A1 (en) 2001-04-05
BG106639A (bg) 2002-12-29
TWI269654B (en) 2007-01-01
RU2282444C2 (ru) 2006-08-27
EP1218006B1 (de) 2010-03-03
ES2342042T3 (es) 2010-07-01
HUP0202788A2 (hu) 2003-01-28
NO322614B1 (no) 2006-11-06
JP2003510274A (ja) 2003-03-18
HRP20020369A2 (en) 2004-12-31
GEP20043250B (en) 2004-06-25
NZ517988A (en) 2004-10-29
UA75872C2 (en) 2006-06-15
DE50015879D1 (de) 2010-04-15
WO2001022954A3 (de) 2002-03-28
AR025885A1 (es) 2002-12-18
CZ303246B6 (cs) 2012-06-20
AU783436B2 (en) 2005-10-27
NO20021367L (no) 2002-05-22
AU7782900A (en) 2001-04-30
SK287533B6 (sk) 2011-01-04
ZA200202556B (en) 2003-08-27
IS6319A (is) 2002-03-21
WO2001022954A2 (de) 2001-04-05
HK1048941B (zh) 2007-09-21
HK1048941A1 (en) 2003-04-25
HUP0202788A3 (en) 2003-02-28
CN1301712C (zh) 2007-02-28
IL148670A0 (en) 2002-09-12
EE200200169A (et) 2003-04-15
RS51302B (sr) 2010-12-31
EP1218006A2 (de) 2002-07-03
PL199576B1 (pl) 2008-10-31
CN1376064A (zh) 2002-10-23
CA2386069C (en) 2012-08-14

Similar Documents

Publication Publication Date Title
BR0014378A (pt) Derivados de ácido indolil-3-glioxìlico tendo propriedades terapeuticamente valiosas
BR0109703A (pt) Derivados de piperazina
EP1426375A3 (en) Analgesic spiroindole derivatives
BR0112711A (pt) Derivados de heteroarila e seus usos como medicamentos
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
TR199903191T2 (xx) Vorikonazol i�eren ila� form�lasyonlar�.
BR9712808A (pt) Indol-3-glioxilamidas n-substituìdas com efeito antiasmático, anti-alérgico e imunossupressor/imunomodulador
BR0208338A (pt) Derivados de piridina
BR9909730A (pt) Dihidropirimidinas
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
BR9712523A (pt) Novos derivados de pirazol heterociclilmetil-substituìdos
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
CY1105008T1 (el) Αντιμικροβιακη ενεργοτητα του πρωτου κατιονικου συγκροτηματος της ανθρωπινης λακτοφερρινης
HK1056728A1 (en) Ortho-substituted anthranilic acid amides and their use as medicaments
DK1290011T3 (da) Melphalan-derivater og deres anvendelse som cancer-kemoterapeutiske lægemidler
SE0101932D0 (sv) Pharmaceutical combinations
BR0014355A (pt) Derivados de sapogenina e seu uso no tratamento de disfunção cognitiva
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
BR0213037A (pt) Derivados de pirimidina
TR199900770T2 (xx) Nazal poliplerin tedavisinde bir H+, K+-ATPase'�n kullan�lmas�.
ATE325803T1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
BR0009821A (pt) Emprego de derivados de maduraftalazina como inibidores de citosinas pró-inflamatórias

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ZIOPHARM ONCOLOGY, INC. (US)

Free format text: TRANSFERIDO DE: BAXTER HEALTHCARE S.A.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/00

Ipc: A61K 31/4439 (2009.01), A61K 31/404 (2009.01), A61

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8,11,10(VIII),24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.